FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149507906> ?p ?o ?g. }

• W2149507906 endingPage "325" @default.
• W2149507906 startingPage "319" @default.
• W2149507906 abstract "This phase II study assessed the efficacy and safety of oral vinorelbine given weekly in combination with carboplatin (CBDCA) AUC 5 once every 3 weeks for four cycles in chemonaive patients with advanced non-small cell lung carcinoma (NSCLC), followed by consolidation therapy with single-agent oral vinorelbine in non-progressive patients.Chemonaive advanced NSCLC patients received four cycles of combination therapy with CBDCA AUC 5 day 1 and oral vinorelbine, 60 mg/m2 on days 1, 8 and 15 (cycle 1), dose increased to 80 mg/m2 (cycles 2-4) in absence of grades 3-4 neutropenia (NCI-CTCv2). Consolidation therapy with oral vinorelbine was continued (cycle 5) at same dosage; if dose was decreased during combination therapy, it was given at 60 mg/m2, then increased at 80 mg/m2 (cycle 6) in absence of grades 3-4 neutropenia until PD, toxicity or patient's refusal.A total of 57 patients were registered and 56 patients were treated (ITT population), median age was 61 years (37-71). Objective response evaluated by RECIST was 17.9% (95% confidence interval, CI [8.9-30.4]) and disease control (CR, PR, NC) 73.2% (95% CI [59.7-84.2]), median progression-free survival 4.3 months (95% CI [3.1-5.1]) with median overall survival 9.7 months (95% CI [7.7-11.9]) and 1-year survival 37.1% (95% CI [24.4, 49.9]). Grades 3-4 neutropenia occurred in 67.9% of patients during combination and 20% during consolidation; febrile neutropenia occurred in 4 patients (7.1%) during combination therapy. Non-hematological toxicities occurred primarily during combination (grade 3 nausea and grade 3 vomiting in 7.1% of patients).The combination of oral vinorelbine given weekly in 3-week cycles in combination with carboplatin followed by consolidation therapy with oral vinorelbine as a single-agent was able to achieve efficacy results in line with other doublets including carboplatin in terms of response as well as survival. This regimen reported a good profile of tolerability in the treatment of advanced NSCLC, allowing that this combination can be easily proposed for the palliative care of NSCLC patients where the advantages of carboplatin over cisplatin are still appreciated." @default.
• W2149507906 created "2016-06-24" @default.
• W2149507906 creator A5001596342 @default.
• W2149507906 creator A5010872796 @default.
• W2149507906 creator A5018915978 @default.
• W2149507906 creator A5022229698 @default.
• W2149507906 creator A5029496175 @default.
• W2149507906 creator A5044842800 @default.
• W2149507906 creator A5046728958 @default.
• W2149507906 creator A5083469127 @default.
• W2149507906 date "2009-06-01" @default.
• W2149507906 modified "2023-09-26" @default.
• W2149507906 title "Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma" @default.
• W2149507906 cites W1935885922 @default.
• W2149507906 cites W1965734230 @default.
• W2149507906 cites W1984254136 @default.
• W2149507906 cites W2014323749 @default.
• W2149507906 cites W2018632519 @default.
• W2149507906 cites W2028235810 @default.
• W2149507906 cites W2055951561 @default.
• W2149507906 cites W2070536874 @default.
• W2149507906 cites W2077980919 @default.
• W2149507906 cites W2079707747 @default.
• W2149507906 cites W2113003672 @default.
• W2149507906 cites W2115684400 @default.
• W2149507906 cites W2127405377 @default.
• W2149507906 cites W2136503777 @default.
• W2149507906 cites W2139248078 @default.
• W2149507906 cites W2145653040 @default.
• W2149507906 cites W2147839112 @default.
• W2149507906 cites W2151518427 @default.
• W2149507906 cites W2154442955 @default.
• W2149507906 cites W2166399931 @default.
• W2149507906 cites W2167959488 @default.
• W2149507906 cites W2169518833 @default.
• W2149507906 cites W2222961311 @default.
• W2149507906 cites W2280399935 @default.
• W2149507906 cites W2331645273 @default.
• W2149507906 cites W2331910443 @default.
• W2149507906 cites W2413435579 @default.
• W2149507906 cites W4239714259 @default.
• W2149507906 doi "https://doi.org/10.1016/j.lungcan.2008.10.014" @default.
• W2149507906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19095327" @default.
• W2149507906 hasPublicationYear "2009" @default.
• W2149507906 type Work @default.
• W2149507906 sameAs 2149507906 @default.
• W2149507906 citedByCount "18" @default.
• W2149507906 countsByYear W21495079062012 @default.
• W2149507906 countsByYear W21495079062013 @default.
• W2149507906 countsByYear W21495079062014 @default.
• W2149507906 countsByYear W21495079062015 @default.
• W2149507906 countsByYear W21495079062016 @default.
• W2149507906 countsByYear W21495079062017 @default.
• W2149507906 countsByYear W21495079062018 @default.
• W2149507906 countsByYear W21495079062020 @default.
• W2149507906 countsByYear W21495079062021 @default.
• W2149507906 crossrefType "journal-article" @default.
• W2149507906 hasAuthorship W2149507906A5001596342 @default.
• W2149507906 hasAuthorship W2149507906A5010872796 @default.
• W2149507906 hasAuthorship W2149507906A5018915978 @default.
• W2149507906 hasAuthorship W2149507906A5022229698 @default.
• W2149507906 hasAuthorship W2149507906A5029496175 @default.
• W2149507906 hasAuthorship W2149507906A5044842800 @default.
• W2149507906 hasAuthorship W2149507906A5046728958 @default.
• W2149507906 hasAuthorship W2149507906A5083469127 @default.
• W2149507906 hasConcept C126322002 @default.
• W2149507906 hasConcept C141071460 @default.
• W2149507906 hasConcept C2776694085 @default.
• W2149507906 hasConcept C2777063308 @default.
• W2149507906 hasConcept C2778239845 @default.
• W2149507906 hasConcept C2778850193 @default.
• W2149507906 hasConcept C2779984678 @default.
• W2149507906 hasConcept C2780350996 @default.
• W2149507906 hasConcept C2781451048 @default.
• W2149507906 hasConcept C31760486 @default.
• W2149507906 hasConcept C71924100 @default.
• W2149507906 hasConcept C90924648 @default.
• W2149507906 hasConceptScore W2149507906C126322002 @default.
• W2149507906 hasConceptScore W2149507906C141071460 @default.
• W2149507906 hasConceptScore W2149507906C2776694085 @default.
• W2149507906 hasConceptScore W2149507906C2777063308 @default.
• W2149507906 hasConceptScore W2149507906C2778239845 @default.
• W2149507906 hasConceptScore W2149507906C2778850193 @default.
• W2149507906 hasConceptScore W2149507906C2779984678 @default.
• W2149507906 hasConceptScore W2149507906C2780350996 @default.
• W2149507906 hasConceptScore W2149507906C2781451048 @default.
• W2149507906 hasConceptScore W2149507906C31760486 @default.
• W2149507906 hasConceptScore W2149507906C71924100 @default.
• W2149507906 hasConceptScore W2149507906C90924648 @default.
• W2149507906 hasIssue "3" @default.
• W2149507906 hasLocation W21495079061 @default.
• W2149507906 hasLocation W21495079062 @default.
• W2149507906 hasOpenAccess W2149507906 @default.
• W2149507906 hasPrimaryLocation W21495079061 @default.
• W2149507906 hasRelatedWork W1975832547 @default.
• W2149507906 hasRelatedWork W1978729515 @default.
• W2149507906 hasRelatedWork W2000712602 @default.
• W2149507906 hasRelatedWork W2026188979 @default.

• next